Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Pancreatin→

Pancreatin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
8049-47-6
Molecular formula
C13H17NO4S
Molecular weight
283.35 g/mol
Drug class
Pancreatic enzyme replacement mixturelipase, amylase and protease enzymes
Mechanism of action
Provides exogenous pancreatic enzymes to digest dietary triglycerides, carbohydrates and proteins in the gastrointestinal tract. Lipase hydrolyses triglycerides, amylase breaks down starch and proteases digest proteins.
Indications / reported uses
  • Enzyme replacement therapy for exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy or other pancreatic disorders; dosing is based on lipase units and meal content, and formulations are not interchangeable without dose adjustment

Sources: US DailyMed — Pancrelipase products · NLM MeSH — Pancreatin · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Pancreatin Environmental Risk Assessment (ERA) (the Pancreatin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.